This novel coronavirus situation is very severe. All the companies in our field need to act rapidly. We need rapid diagnostic tools to detect the novel coronavirus, and we are taking part in that fight.
Summary sheet
The project consists of the financing of Mobidiag, an innovative medtech company based in Finland. This financing will help Mobidiag to develop new diagnostic tests for infectious diseases.
The proposed transaction will support research and development (R&D) investments that are required in order to further advance the promoter's product pipeline and bring the products to market.
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Documents
News & Stories
Inside the project
How and Why
Testing and screening
Why
- The coronavirus pandemic has created a need for fast, reliable, large-scale testing solutions that could be operated also by people without training in diagnostics
- The field of diagnostics will be critical in the fight against pandemics like the coronavirus and in the future.
How
- Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of most clinically relevant bacteria, parasites, viruses and antibiotic resistances
- The EIB financing supports the development of two testing machines for the rapid molecular diagnostics of coronavirus infection: Novodiag and Amplidiag
- Based on well-established qPCR and microarray technologies, these machines combine high quality and affordable costs and offer a complete solution for rapid molecular diagnostics of coronavirus infection.
Sectors & Countries
Play video
1:06

By supporting the development of in-vitro testing platforms and facilities, we have been able to provide a crucial service in Europe in these difficult times.
Related media
Health Solutions: The pandemic next time
Health Solutions: Caught out by a pandemic
Related projects and stories
EIB Group opens country office in Belgium to support strategic investments in Belgian economy
The European Investment Bank (EIB) Group has opened a country office in Belgium, dedicated to sustaining strategic financing and sustainable growth in the country as a boost to the potential of the vibrant, dynamic and highly innovative Belgian business environment. The new office will be hosted in the Group’s Permanent EU Representation in Brussels and led by Torsten Brand, a dual Belgian-German national who has worked at the EIB for the past decade. The step by the Luxembourg-based EIB Group, which also includes the European Investment Fund (EIF), underscores its commitment to supporting the Belgian economy and deepening engagement with local businesses and the public sector.
Cocoa with a conscience: Funding fair and forest‑friendly beans
EIB finance helps Ivory Coast produce sustainable cocoa that avoids deforestation and child labour while improving agricultural practices
Where will we live? The urgent need for affordable housing in Estonia
The European Investment Bank is helping Estonia build and renovate homes so that families, workers, and communities can have affordable places to live.
Videos

Learn more

Learn more

Learn more